Transmembrane proteases as disease markers and targets for therapy

Journal of Biological Regulators and Homeostatic Agents

Volumn 15, Issue 2, 2001, Pages 130-139

  Antczak, C ^a   De Meester, I ^a   Bauvois, B ^a  

^a INSTITUT CURIE   (France)

Author keywords

Cancer; Ectoenzyme; Ectopeptidase; Inhibitor; Leukemia; Vasopeptidase

Indexed keywords

ACIVICIN; ACTINONIN; ANTIBODY CONJUGATE; BESTATIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECTOPROTEINASE; ENALAPRILAT; FASIDOTRIL; MEMBRANE ASSOCIATED PROTEINASE; OMAPATRILAT; PROTEINASE; PROTEINASE INHIBITOR; SA 7060; UNCLASSIFIED DRUG; Z 13752 A;

ACUTE LEUKEMIA; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE MARKER; DRUG DESIGN; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; ENDOTHELIUM CELL; EPITHELIUM CELL; ERYTHROCYTOSIS; HAMSTER; HEMATOPOIETIC CELL; HUMAN; HYPERTENSION; LUNG SMALL CELL CANCER; MEDICAL RESEARCH; MODULATION; MOUSE; MUCOSA INFLAMMATION; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; RAT; REVIEW; SOLID TUMOR; TISSUE TYPES;

ANIMALIA; CRICETINAE;

EID: 0034884396     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Hematopoietic differentiation antigens that are membrane-associated enzymes: Cutting is the key
2. Ecto-enzymes: Physiology meets pathology
3. Ectopeptidases in pathophysiology
4. Genetic and physiological aspects of angiotensin I-converting enzyme
5. The neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function
6. CD13 - Not just a marker in leukemia typing
7. CD26, let it cut or cut it down
8. Role of alanyl aminopeptidase in growth and function of human T cells
9. Membrane-type matrix metalloproteinases
10. The ADAM gene family. Surface proteins with adhesion and protease activity
11. Transmembrane proteases in focus: Diversity and redundancy?
12. Expression of cell-surface peptidases in neoplastic cells
13. Dipeptidyl peptidase IV: A cell surface peptidase involved in regulating T cell growth
14. Dipeptidyl peptidase activity of CD26 in serum and urine as a marker of cholestasis: Experimental and clinical evidence
15. Dipeptidyl peptidase IV (DPPIV/CD26) staining predicts distant metastasis of 'benign' thyroid tumor
16. Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma
17. Variable expression in normal human lung and inactivation in lung cancer
18. Preoperative serum CD26 levels: Diagnostic efficiency and predictive value for colorectal cancer
19. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells
20. Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer
21. Utility of serum activity of angiotensin-converting enzyme as a tumour marker
22. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinoma
23. Role of MT-MMPs and MMP-2 in pancreatic cancer progression
24. Critical analysis and diagnostic usefulness of limited immunophenotyping of B-cell non-Hodgkin lymphomas by flow cytometry
25. Matrix metalloproteinase production by bone mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes
26. Expression of CD26 and DPPIV in T-acute lymphoblastic leukemia: Comparison of immunocytochemistry with enzyme cytochemistry
27. Dipeptidyl peptidase IV-subcellular localization, activity and kinetics in lymphocytes from control subjects, immunodeficient patients and cord blood
28. Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals
29. Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis
30. Staining pattern of seven monoclonal anti-CD26 antibodies in leprosy: Implications for the use of CD26 as a surrogate marker of a human Th1-like reaction
31. Increased expression of neutral endopeptidase (NEP) and aminopeptidase N (APN) on peripheral blood mononuclear cells in patients with multiple sclerosis
32. A guardian angel: The involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence
33. Defect of T helper lymphocytes, as identified by the 5/9 monoclonal antibody, in patients with common variable hypogammaglobulinaemia
34. Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy
35. The chemistry and pharmacology of cell-surface peptidase inhibitors
36. Aminopeptidases: Towards a mechanism of action
37. Metabolism of bradykinin by peptidases in health and disease
38. Design of angiotensin converting enzyme inhibitors
39. Potentiation of bradykinin actions by ACE inhibitors
40. Overview of the angiotensin-converting enzyme inhibitors
41. Protease inhibitors: Current status and future prospects
42. Lisinopril: A review of its use in congestive heart failure
43. Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: Predominant role of angiotensin III in the control of vasopressin release
44. PC18, a specific aminopeptidase inhibitor, induces vasopressin release by increasing the half-life of brain angiotensin III
45. Investigation of the active site of aminopeptidase A using a series of new thiol-containing inhibitors
46. Aminopeptidase A inhibitors as potential central antihypertensive agents
47. Potent and selective inhibition of zinc aminopeptidase A (EC 3.4.11.7, APA) by glutamyl aminophosphonic peptides: Importance of glutamyl aminophosphinic residue in the P1 position
48. Mixed inhibitor drug as a new approch toward systemically active inhibitors of enkephalin-degrading enzymes
49. Vasopeptidase inhibition: A new concept in blood pressure management
50. Effects of SA7060, a novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, on deoxycortisone acetate-salt-induced hypertension in rats
51. A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and volunteers
52. Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans
53. The unique properties of dipeptidyl-peptidase IV (DPPP IV/CD26) and the therapeutic potential of DPP IV inhibitors
54. (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]-2-cyano-(S)-pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV
55. Potent inhibitors of dipeptidyl peptidase IV and their mechanisms of inhibition
56. Thioxo amino acid pyrrolidides and thiazolidides: New inhibitors of proline specific peptidases
57. Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors
58. 1-aminomethylisoquinoline-4-carboxylates as novel dipeptidyl peptidase IV inhibitors
59. Interaction of γ-glutamyl transpeptidase with acivicin
60. Isolation of anthglutin, an inhibitor of γ-glutamyl transpeptidase from Penicillum oxalicum
61. Development and evaluation of a boronate inhibitor of γ-glutamyl transpeptidase
62. Involvement of ser-451 and ser-452 in the catalysis of human γ-glutamyl transpeptidase
63. Captopril inhibits apoptotosis in human lung epithelial cells: A potential antifibrotic mechanism
64. Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell-activation signals
65. Does captopril have a direct pro-apoptotic effect?
66. Neutral endopeptidase modulates substance P-induced vasodilation in vivo
67. Effects of erythropoietin, angiotensin II, and angiotensin-converting enzyme inhibitor on erythroid precursors in patients with posttransplantation erythrocytosis
68. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
69. Effects of omapatrilat on systemic arterial function in patients with chronic heart failure
70. Antihypertensive and antihypertrophic effects of omapatrilat in SHR
71. Comparison of vasopeptidase inhibitor, omapatrilat and lisinopril on exercise tolerance and morbidity in patients with heart failure
72. Vasopeptidase inhibition: A new direction in cardiovascular treatment
73. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats
74. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis
75. Kidney aminopeptidase A and hypertension, part II: Effects of angiotensin II
76. Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure
77. CD26/DPPIV-mediated modulation of acute rejection
78. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig
79. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide
80. Improved glucose tolerance in rats treated with the dipeptidyl peptidase (DPPIV) inhibitor Ile-thiazolidide
81. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
82. DPPIV inhibition as treatment of type 2 diabetes
83. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and upregulates TGF-b1 secretion in vivo
84. Suppressive activity of acivicin on murine bone marrow hemopoietic progenitors
85. The effects of a leukaemia-controlling dose of acivicin on murine splenic lymphocytes in vitro and in vivo
86. Carrier-mediated transport of the antitumor agent acivicin across the blood-brain barrier
87. Acivicin: A new glutamine antagonist in clinical trials
88. A phase I study of acivicin in refractory pediatric solid tumors. A pediatric oncology group study
89. Phase I-II trial of acivicin in adult acute leukemia
90. Phase II trial of continuous drug infusions in advanced ovarian carcinoma; acivicin versus vinblastine
91. Targeting of drugs to cell surface receptors
92. Targeted delivery of chemotherapeutics : Tumor-activated prodrug therapy
93. Monoclonal antibody-based therapies for hematologic malignancies
94. Anti-MY9-blocked ricin: An immunotoxin for selective targeting of acute myeloid leukemia cells
95. Clinical studies of new "biologic" approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates
96. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases
97. Immunotoxin therapy of small-cell lung cancer : A phase I study of N901-blocked ricin
98. Antibody-directed enzyme prodrug therapy (ADEPT): A review
99. Antibody directed enzyme prodrug therapy (ADEPT): A review of the experimental and clinical considerations
100. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human β-glucuronidase for antibody-directed enzyme prodrug therapy
101. Monoclonal antibody-based therapy